Our Pricing

Is Wegovy Safe? UK Pharmacist's Evidence-Based Safety Guide

Is Wegovy safe for weight loss in the UK? As a registered UK pharmacist who has guided thousands of patients through their weight management journeys, I can confirm that Wegovy (semaglutide 2.4mg) is a MHRA-licensed, clinically proven treatment with an established safety profile when used under proper medical supervision. The STEP clinical trial programme, involving over 4,500 participants, demonstrated that Wegovy is generally well-tolerated, with most side effects being mild to moderate gastrointestinal symptoms that typically resolve within weeks [1]. However, like all prescription medications, Wegovy carries specific contraindications and requires careful assessment by a UK prescriber to ensure it's appropriate for your individual health circumstances.

Is Wegovy Safe? Clinical Trial Evidence and MHRA Approval

The question 'is Wegovy safe?' is best answered by examining the robust clinical evidence that led to its MHRA approval in 2023. The STEP (Semaglutide Treatment Effect in People with obesity) trials evaluated semaglutide 2.4mg in over 4,500 adults across multiple studies, with treatment durations up to 68 weeks [1]. These trials showed that 74% of participants completed the full study period, indicating good overall tolerability. The safety profile was consistent across different patient populations, including those with type 2 diabetes and cardiovascular risk factors.

Wegovy received regulatory approval from the MHRA following comprehensive review of safety data, including long-term cardiovascular outcomes. The medication belongs to the GLP-1 receptor agonist class, which has been used in diabetes management since 2005, providing nearly two decades of real-world safety data [2]. At Cured Pharmacy, we ensure every patient undergoes clinical assessment by our UK-registered prescribers before Wegovy is dispensed, with superintendent pharmacist Tarun Kumar (GPhC 2233073) overseeing all prescribing protocols to maintain the highest safety standards.

Is Wegovy Safe? Understanding Common Side Effects

When patients ask 'is Wegovy safe?', they're often concerned about side effects. The most commonly reported adverse effects in clinical trials were gastrointestinal: nausea (44%), diarrhoea (30%), vomiting (24%), and constipation (24%) [1]. These symptoms are typically mild to moderate in severity and tend to diminish significantly after the first 8-12 weeks as your body adjusts to the medication. The gradual dose escalation protocol—starting at 0.25mg weekly and increasing every four weeks—is specifically designed to minimise these effects.

Serious adverse events were rare in the STEP trials, occurring in approximately 9.8% of Wegovy users compared to 6.4% in the placebo group [1]. Most serious events were not directly attributed to the medication itself. However, Wegovy does carry warnings for specific conditions including pancreatitis, gallbladder disease, and potential thyroid tumours (based on rodent studies, though no human cases have been confirmed) [3]. Our clinical team at Cured Pharmacy carefully screens for risk factors during your online consultation to ensure Wegovy is safe for your individual circumstances.

Managing Side Effects Safely

If you experience side effects whilst taking Wegovy, several evidence-based strategies can help. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated significantly reduce gastrointestinal symptoms for most patients. Taking your injection on the same day each week, preferably in the evening after your main meal, can also improve tolerability. Our pharmacist team provides personalised guidance on managing side effects whilst maintaining treatment efficacy—support that's included in your £20 treatment cost at Cured Pharmacy.

Is Wegovy Safe for You? Contraindications and Who Should Avoid It

Determining 'is Wegovy safe?' requires understanding who should not use this medication. Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [3]. It should not be used during pregnancy or breastfeeding, and women of childbearing age should use effective contraception and discontinue Wegovy at least two months before planned conception.

Patients with a history of severe gastrointestinal disease, including inflammatory bowel disease or gastroparesis, require careful evaluation before starting Wegovy. Those with active or history of pancreatitis, severe renal impairment, or proliferative diabetic retinopathy should discuss alternative weight loss options with their prescriber [2]. Additionally, Wegovy may interact with certain medications, particularly insulin and sulfonylureas, requiring dose adjustments to prevent hypoglycaemia.

Safety Monitoring During Treatment

Safe use of Wegovy involves ongoing monitoring throughout your treatment journey. Your prescriber will typically recommend baseline assessments and periodic reviews to monitor for potential complications. Signs that require immediate medical attention include severe abdominal pain (possible pancreatitis), vision changes, persistent nausea or vomiting, or signs of allergic reaction [3]. At Cured Pharmacy, we provide continuous access to our clinical team for safety concerns, ensuring you're never managing potential issues alone—this comprehensive care is part of our commitment to safe, effective weight loss treatment from £69.00.

Is Wegovy Safe Long-Term? Extended Use Safety Data

For patients considering extended treatment, the question 'is Wegovy safe long-term?' is particularly important. The STEP 5 trial followed participants for 104 weeks (two years), providing valuable data on prolonged use [4]. This study showed that the safety profile remained consistent over time, with no new safety signals emerging during extended treatment. Participants maintained significant weight loss throughout the study period without increased adverse events.

Long-term cardiovascular safety is a critical consideration for any weight loss medication. The SELECT trial, which evaluated semaglutide 2.4mg in over 17,000 participants with cardiovascular disease, demonstrated a 20% reduction in major adverse cardiovascular events compared to placebo [5]. This landmark study not only confirmed Wegovy's safety in high-risk populations but also revealed potential cardiovascular benefits beyond weight loss. However, it's important to note that Wegovy is intended for chronic weight management—discontinuation typically results in weight regain, so patients should view this as a long-term commitment rather than a short-term intervention.

Is Wegovy Safe Compared to Other Weight Loss Treatments?

When evaluating 'is Wegovy safe?', many patients want to understand how it compares to alternative weight loss medications. Wegovy's safety profile is generally favourable compared to older weight loss drugs that were withdrawn due to cardiovascular risks. Unlike medications such as sibutramine (withdrawn in 2010), GLP-1 receptor agonists like Wegovy have demonstrated cardiovascular benefits rather than risks [5].

Compared to Orlistat, the other commonly prescribed weight loss medication in the UK, Wegovy shows different side effect patterns. Orlistat primarily causes gastrointestinal effects related to fat malabsorption, whilst Wegovy's effects are mediated through appetite regulation and delayed gastric emptying [2]. Mounjaro (tirzepatide), a newer dual GLP-1/GIP agonist, shows a similar safety profile to Wegovy with comparable gastrointestinal side effects but potentially greater efficacy in clinical trials. The choice between these medications depends on individual patient factors, medical history, and treatment goals—all assessed during your clinical consultation at Cured Pharmacy.

Safety Considerations for Specific Populations

Wegovy's safety varies across different patient populations. In adults over 65, clinical trial data is more limited, though available evidence suggests similar safety profiles to younger adults, with careful monitoring recommended [1]. Patients with type 2 diabetes require particular attention to blood glucose monitoring, as Wegovy may enhance the glucose-lowering effects of other diabetes medications. Those with a BMI between 27-30 kg/m² with weight-related comorbidities can safely use Wegovy, though careful benefit-risk assessment is essential at lower BMI ranges.

Is Wegovy Safe? How Cured Pharmacy Ensures Your Safety at £89

At Cured Pharmacy, ensuring Wegovy is safe for each individual patient is our paramount concern. Every order requires completion of a comprehensive online clinical assessment reviewed by our UK-registered prescribers. This assessment evaluates your medical history, current medications, contraindications, and individual risk factors to determine whether Wegovy is appropriate and safe for you. Unlike some online providers, we never auto-approve prescriptions—each assessment receives individual clinical review.

Our commitment to safety extends beyond the initial prescription. We provide ongoing clinical support throughout your treatment, with direct access to our pharmacist team for any safety concerns or side effect management. Superintendent pharmacist Tarun Kumar (GPhC 2233073) personally oversees our clinical protocols, ensuring every patient receives the same standard of care you'd expect from a traditional pharmacy, but with the convenience and competitive pricing of our online service. We supply only genuine, UK-licensed Wegovy sourced directly from licensed wholesalers, with full cold-chain integrity maintained throughout storage and dispatch.

When you choose Cured Pharmacy for your Wegovy treatment at £69.00 you're not just getting the cheapest UK price—you're accessing a fully regulated, GPhC-registered pharmacy (9012511) with transparent pricing, expert clinical oversight, and genuine commitment to your safety. We believe affordable weight loss treatment should never compromise on clinical standards, which is why we've built our service around the same rigorous safety protocols that govern traditional pharmacy practice, whilst leveraging online efficiency to offer the most competitive pricing in the UK market.

Scientific References

1. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 2.4mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. [accessed 15 August 2026]
3. Novo Nordisk. (2023). Wegovy (semaglutide) injection prescribing information. Novo Nordisk A/S. [accessed 15 August 2026]
4. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., ... & Wharton, S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 15 August 2026]
5. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., ... & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232. [accessed 15 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.